Drug Trial Radar · NCT04869358
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
Last checked: Nov 20, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
May 27, 2021
Primary completion
May 10, 2022
Study completion Jun 13, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aimed to understand whether patients with relapsing multiple sclerosis (RMS) can mount an immune response to SARS-CoV-2 mRNA vaccines (initial vaccinations or booster vaccines) when vaccinated either before initiation of ofatumumab treatment or at least 4 weeks after commencing ofatumumab treatment.
Conditions
- Relapsing Multiple Sclerosis
Interventions
OfatumumabDrug
Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Having Established SARS-CoV-2-specific T Cells After Receiving a modRNA VaccineTime frame: 1 month after second dose of vaccine or booster vaccine
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bielefeld, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Erbach im Odenwald, Germany
Novartis Investigative Site
Siegen, Germany
Novartis Investigative Site
Unterhaching, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.